Versant Venture Management LLC's Q4 2023 13F: 1 exit
Form 13F-HR for the quarter ended Dec 31, 2023 · filed Feb 8, 2024 · 7 reported positions · accession 0000950123-24-001156
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Exited | Minerva Surgical Inc. (UTRS) | 0.1% | — | −0.1 pts | −83,684 sh | −100% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
Changes in the top 10 this quarter: UTRS left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | RayzeBio, Inc. (RYZB) | 60.9% | 82.5% | |
| 2 | CRISPR Therapeutics AG (CRSP) | 12.0% | 8.0% | |
| 3 | Repare Therapeutics, Inc. (RPTX) | 17.0% | 5.0% | |
| 4 | Gritstone Bio, Inc. (GRTS) | 3.3% | 1.9% | |
| 5 | Passage Bio, Inc. (PASG) | 1.7% | 1.3% | |
| 6 | Adverum Biotechnologies, Inc. (ADVM) | 4.0% | 1.0% | |
| 7 | Aligos Therapeutics, Inc. (ALGS) | 0.9% | 0.4% | |
| — | Minerva Surgical Inc. (UTRS) | 0.1% | 0.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).